Avigen Could Yield Considerably More than Its Net Cash Value [View article]
"...AVGN’s AV411 assets"???...what asset?...ibudilast has been used for something like 15 years in Japan for treating asthma and MS...in that period of time, one might think that someone over there might recognize its ability to treat pain and initiate the appropriate trials to test and market it...but did Kyorin Pharmaceutical do that?...nope!...in fact they sold the rights to it to another dinky NASDAQ biotech called Medicinova...not only does that tell you how much Kyorin values the drug, it raises the question of who has the rights to market it...I suspect the drug has a real value of zero and is just being used to dupe naieve investors in order to line the pockets of company management and the brokers who sell the stock.
Avigen Could Yield Considerably More than Its Net Cash Value [View article]
biz.yahoo.com/pz/09020...
...wow, that would have been worth $4 a share...it seems to have disappeared -- wonder why?
Avigen Could Yield Considerably More than Its Net Cash Value [View article]